IFM Investors Pty Ltd Has $3.30 Million Holdings in Insulet Co. (NASDAQ:PODD)

IFM Investors Pty Ltd lessened its stake in Insulet Co. (NASDAQ:PODD) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,180 shares of the medical instruments supplier’s stock after selling 342 shares during the quarter. IFM Investors Pty Ltd’s holdings in Insulet were worth $3,300,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $32,000. Sunbelt Securities Inc. acquired a new stake in shares of Insulet during the 1st quarter worth approximately $29,000. UMB Bank n.a. grew its position in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the period. Finally, CVA Family Office LLC grew its position in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period.

Insulet Stock Performance

Shares of PODD opened at $233.63 on Monday. The firm’s 50 day moving average price is $222.53 and its two-hundred day moving average price is $199.57. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. The firm has a market cap of $16.36 billion, a P/E ratio of 70.80, a PEG ratio of 4.42 and a beta of 1.21. Insulet Co. has a twelve month low of $128.68 and a twelve month high of $243.98.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.38 EPS. On average, analysts forecast that Insulet Co. will post 3.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PODD shares. Citigroup boosted their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. UBS Group boosted their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. BTIG Research boosted their price objective on shares of Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James boosted their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, Barclays boosted their price objective on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $242.29.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.